TRVI Stock Risk & Deep Value Analysis

Trevi Therapeutics, Inc.

DVR Score

6.9

out of 10

Solid Pick

The Bottom Line on TRVI

We analyzed Trevi Therapeutics, Inc. using our deep value framework. Sign in to see our full verdict and DVR Score.

We ran TRVI through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.

Updated Sep 15, 2025•Run Fresh Analysis →

📈TRVI Performance Overview3yr weekly

📊

Unlock TRVI Performance Chart

See 3 years of price history, quarterly revenue trends, and DVR score changes

Weekly adjusted close · Quarterly revenue & EPS · DVR score history

TRVI Deep Value Analysis

Trevi presents a high-risk, high-reward opportunity, driven by its differentiated kappa-opioid agonist, Haduvio, targeting underserved chronic pruritus markets like prurigo nodularis (PN). Existing approval in Japan validates the molecule. The major catalyst is binary Phase 2b/3 PN data (PEARL study) in Q3 2024; positive results could unlock significant 10x growth potential towards market leadership due to unique MOA and oral delivery. However, negative results would lead to an unsustainable financial trajectory, classifying it as a 'dud' despite strategic vision. Cash runway is adequate only if PEARL succeeds, highlighting extreme reliance on this single event.

📈

Unlock the full report

Create a free account to see the DVR score, risk flags, and AI analysis.

🔥 New Member Exclusive

Unlock everything for $47/yr

$79/yrSave 41%

✓ Catalysts, bull case, moat & red flags
✓ Unlimited stock analyses + alerts
✓ Full database, search & portfolio (50 stocks)

Get Premium — $47/yr

7-day money back · Cancel anytime

🔔

Never miss a move on TRVI

Create a free account to set price alerts and get notified on Telegram when TRVI hits your targets.

📊 Explore More Stock Analysis

Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.

Analyze Any Stock →View Top 100 Deep Value Stocks →

FAQ

What is the DVR Score for Trevi Therapeutics, Inc. (TRVI)?

As of September 15, 2025, Trevi Therapeutics, Inc. has a DVR Score of 6.9 out of 10, placing it in the "Solid Pick" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.

How often is the TRVI DVR analysis updated?

Our AI-powered analysis of Trevi Therapeutics, Inc. is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on September 15, 2025.

Important Disclaimer – Not Financial Advice

Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.

All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.